Latest annual review on HIV, HCV and TB drugs, diagnostics, vaccines, preventive technologies, research toward a cure, and immune-based and gene therapies in development.

The letter urges Johns Hopkins to assure the timely and responsible development of TB drug candidate sutezolid if transferring any intellectual property rights to Sequella.

Re: Programmatic and research targets for the Global Plan to Stop TB, 2016–2020

Re: Inclusion of pediatric-specific targets in the Global Plan to Stop TB, 2016-2020

The symposium was held October 30 at the 2014 Union World Conference on Lung Health in Barcelona, Spain.

TB activists interrupted Otsuka’s symposium at the 45^th Conference on Lung Health, calling for widespread registration of and immediate broad compassionate use access to delamanid, Otsuka’s new drug to treat multidrug-resistant TB.

2014 International Union Against TB and Lung Disease World Conference
Date: October 30, 2014
Time: 18h00 - 22h00
Location: Hotel Diagonal Zero Barcelona

TAG’s ninth annual Report on Tuberculosis Research Funding Trends shows that the foundation of the TB research enterprise is shakier than ever, setting back efforts to fight a disease that in 2012 killed 1.3 million people and caused 8.6 million to fall sick.

News on the fight to end HIV/AIDS, viral hepatitis, and tuberculosis

Both guides describe what activists—including people with TB, researchers, and doctors who treat TB—can do to help ensure access, fair pricing, and further research.